Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan with different Endostar administration routes for malignant ascites in recurrent ovarian cancer
ChiCTR1800018359Phase 4Not yet recruiting
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of irinotecan and endostar in ovarian cancer (4 arms), sponsored by Fourth Affiliated Hospital of Guangxi Medical University. Primary endpoints: Objective response rate, Blood CA125 and 1 more. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
irinotecanendostar
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR1800018359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018359.